“The committee’s proposal to exempt certain generic injectable drugs from the vital 340B Program — and thus removing drug manufacturers’ obligations to offer a discounted price for these drugs — is an untenable solution to address drug shortages,” the letter states.
Instead, the AHA asserts that more support should be provided to drugmakers that have demonstrated a commitment to maintaining production of critical, low-cost and accessible medications.
“While the AHA believes shoring up the drug supply chain is of great importance, accomplishing this goal should not come at the cost of patient care,” the letter reads. “Reducing access to the 340B Drug Pricing Program would directly impact hospitals’ ability to offer a wide range of health care services to some of the nation’s most vulnerable populations.”
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.
